Matrix metalloproteinases 2 (MMP2) promotes immunosuppressive TME formation by reducing anti-tumor-associated immune cells (CD4+ and CD8+ T cells, NK cells, and CD103+ DCs) and increasing M2-like macrophages (87). Here, CD8A is linked to neoplasm.